07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

BioArctic, Biotecnol deal

The companies will use Biotecnol’s Tribody technology and BioArctic’s anti-amyloid beta antibodies to develop an in vivo diagnostic tool for Alzheimer’s disease (AD). The research will be conducted at Uppsala University . According to Biotecnol,...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Biotecnol Inc., Chiome deal

The companies partnered to co-develop multi-specific Tribody molecules against undisclosed targets to treat cancer using Chiome's ADlib antibody generating system and Biotechnol's Tribody technology. Tribody molecules are multi-specific antibody products that use heterodimerization of Fab...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Biotecnol Inc., PolyTherics deal

Biotecnol and PolyTherics partnered to develop multi-specific Tribody drug conjugates to treat cancer. The companies will use PolyTherics' ThioBridge conjugation technology to attach cytotoxic drugs on Biotecnol's Tribody molecules. Tribody molecules are multi-specific antibody products...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Cardiotrophin-1 regulatory update

FDA and the European Commission granted Orphan Drug designation for Digna's cardiotrophin-1 to treat acute liver failure. The recombinant human CT-1 is in Phase I testing to treat ischemic and reperfusion injuries associated with liver...
07:00 , Aug 25, 2011 |  BC Innovations  |  Cover Story

Cardiotrophin workout

A team at the University of Navarra has shown that obesity and metabolic syndrome can be treated with cardiotrophin-1, a cytokine that regulates energy utilization and appetite. 1 The findings open up a new indication...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

Cardiotrophin-1: Phase I start

Next quarter, Digna and Biotecnol will start a dose-escalation, Spanish Phase I trial to evaluate 0.3-180 µg/kg doses of IV CT-1 in 33 healthy volunteers. The partners are developing CT-1 under an amended 2007 deal...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

Biotecnol S.A., Digna Biotech, Roche deal

Biotecnol and partner Digna received exclusive rights to Roche's Genentech Inc. unit's patents covering cardiotrophin-1 (CT-1) proteins for use in certain liver indications. Genentech will receive an undisclosed payment and has an exclusive option to...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Biotecnol, Digna Biotech preclinical data

In rabbit models of fulminant hepatitis, CT-1 improved survival rates vs. control at 36 hours post-infection (100% vs. 55%) and at 60 hours post infection (80% vs. 18%). At 168 hours post-infection, 33% of rabbits...
08:00 , Feb 16, 2009 |  BC Week In Review  |  Company News

Biotecnol management update

Biotecnol S.A. , Oeiras, Portugal   Business: Cancer, Antibodies   Appointed: Nico Mertens as director of antibody engineering programs  ...
08:00 , Feb 9, 2009 |  BC Week In Review  |  Company News

Biotecnol S.A., INSERM, Hopitaux Universitaires de Strasbourg, Universite Louis Pasteur deal

The institutions granted Biotecnol an exclusive, worldwide license to develop and commercialize IP covering parathyroid hormone-related protein (PTHrP) antagonists to treat renal cell carcinoma (RCC). Biotecnol will use the IP with its Tribody antibody-engineering technology...